LEO Pharma Secures FDA Priority Review for Dersimelagon, Closes $435M Acquisition
Event summary
- FDA accepted LEO Pharma's NDA for dersimelagon with Priority Review, setting a PDUFA action date by February 2027.
- LEO Pharma closed the acquisition of worldwide rights to dersimelagon from Tanabe Pharma for up to $435M.
- Dersimelagon is a potential first-in-class oral therapy for rare skin diseases EPP and XLP.
- The acquisition strengthens LEO Pharma's late-stage rare dermatology pipeline.
The big picture
LEO Pharma's acquisition of dersimelagon and the FDA's Priority Review mark a strategic push into rare dermatology, complementing its recent deals in gene therapy and autoimmune treatments. The $435M investment underscores the company's commitment to addressing unmet medical needs in severe skin diseases, positioning it as a leader in medical dermatology. The success of dersimelagon could further solidify LEO Pharma's pipeline and market presence.
What we're watching
- Regulatory Success
- Whether the FDA Priority Review will lead to a timely approval of dersimelagon by February 2027.
- Commercialization Strategy
- How LEO Pharma will leverage its global platform to commercialize dersimelagon if approved.
- Pipeline Integration
- The pace at which LEO Pharma can integrate dersimelagon into its broader rare dermatology portfolio.
Related topics